Crossmark

Frontline immunotherapy for NSCLC: alone or not alone?

Crossref DOI link: https://doi.org/10.1038/s41571-018-0070-7

Published Online: 2018-07-11

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gridelli, Cesare

Casaluce, Francesca
License Information

Text and Data Mining valid from 2018-07-11
More Information

Article History

First Online: 11 July 2018

Competing interests

: C.G. has received honoraria as speaker bureau and is an advisory board member for AstraZeneca, Bristol-Myers Squibb (BMS), MSD, and Roche. F.C. declares no competing interests.